METHODS AND COMPOSITIONS FOR THE TREATMENT OF RECEPTOR TYROSINE KINASE MEDIATED DISEASES OR DISORDERS
The present disclosure provides methods and compositions for treating a disease or disorder in a subject, the method comprising, administering to the subject a therapeutically effective amount of one or more receptor tyrosine kinase inhibitors and a therapeutically effective amount of one or more inhibitors of the dihydrofolate reductase (DHFR) pathway including, for example, methyltransferase inhibitors.
1 . A method for sensitizing and treating a cell harboring a Ras mutation, the method comprising,
contacting the cell with a therapeutically effective amount of one or more inhibitors of the dihydrofolate reductase (DHFR) pathway; and
contacting the cell with a therapeutically effective amount of one or more receptor tyrosine kinase inhibitors.
2 . The method of claim 1 , wherein the inhibitor of the DHFR pathway is a methyltransferase inhibitor.
3 . The method of claim 2 , wherein the methyltransferase inhibitor is Methotrexate.
4 . The method of claim 1 , wherein Ras is k-Ras (SEQ ID NO: 1), n-Ras (SEQ ID NO: 2) or h-Ras (SEQ ID NO: 3).
5 . The method of claim 4 , wherein the k-Ras mutations are at position 12, 13 or 61.
6 . The method of claim 5 , wherein the k-Ras mutations are selected from the group consisting of: G12A, G12N, G12R, G12C, G12S, G12V, G13N and Q61H.
7 . The method of claim 4 , wherein the h-Ras or n-Ras mutations are at positions 12, 13 or 61.
8 . The method of claim 1 , wherein the receptor tyrosine kinase inhibitor is an antibody.
9 . The method of claim 1 , wherein the tyrosine kinase inhibitor targets HER1 (EGFR), HER2/neu, HER3, or any combination thereof.
10 . The method of claim 8 , wherein the antibody is a monoclonal antibody.
11 . The method of claim 10 , wherein the monoclonal antibody is cetuximab (Erbitux), panitumumab, zalutumumab, nimotuzumab or matuzumab.
12 . The method of claim 1 , wherein the receptor tyrosine kinase inhibitor is a small molecule inhibitor.
13 . The method of claim 12 , wherein the small molecule inhibitor is gefitinib, erlotinib or lapatinib.
14 . A method for treating a disease or disorder in a subject, the method comprising, administering to the subject a therapeutically effective amount of one or more receptor tyrosine kinase inhibitors and a therapeutically effective amount of one or more inhibitors of the dihydrofolate reductase (DHFR) pathway.
15 . The method of claim 14 , wherein the inhibitor of the DHFR pathway is a methyltransferase inhibitor.
16 . The method of claim 15 , wherein the methyltransferase inhibitor is Methotrexate.
17 . The method of claim 14 , wherein the disease or disorder is characterized by one or more Ras mutations.
18 . The method of claim 17 , wherein Ras is k-Ras (SEQ ID NO: 1), n-Ras (SEQ ID NO: 2) or h-Ras (SEQ ID NO: 3).
19 . The method of claim 18 , wherein the k-Ras mutations are at position 12, 13 or 61.
20 . The method of claim 19 , wherein the k-Ras mutations are selected from the group consisting of: G12A, G12N, G12R, G12C, G125, G12V, G13N and Q61H.
21 . The method of claim 18 , wherein the h-Ras or n-Ras mutations are at positions 12, 13 or 61.
22 . The method of claim 14 , wherein the receptor tyrosine kinase inhibitor is an antibody.
23 . The method of claim 14 , wherein the tyrosine kinase inhibitor targets HER1 (EGFR), HER2/neu, HER3, or any combination thereof.
24 . The method of claim 22 , wherein the antibody is a monoclonal antibody.
25 . The method of claim 24 , wherein the monoclonal antibody is cetuximab (Erbitux), panitumumab, zalutumumab, nimotuzumab or matuzumab.
26 . The method of claim 14 , wherein the receptor tyrosine kinase inhibitor is a small molecule inhibitor.
27 . The method of claim 26 , wherein the small molecule inhibitor is gefitinib, erlotinib or lapatinib.
28 . The method of claim 14 , wherein the therapeutically effective amount of one or more tyrosine kinase inhibitors and the therapeutically effective amount of one or more methyl-transferase inhibitors are optionally adapted for a co-treatment with radiotherapy or radio-immunotherapy.
29 . The method of claim 14 , wherein the disease or disorder is cancer.
30 . The method of claim 29 , wherein the cancer is selected from the group consisting of gastrointestinal cancer, prostate cancer, ovarian cancer, breast cancer, head and neck cancer, lung cancer, non-small cell lung cancer, cancer of the nervous system, kidney cancer, retina cancer, skin cancer, liver cancer, pancreatic cancer, genital-urinary cancer and bladder cancer.
31 . The method of claim 14 , wherein the subject is a cancer patient.
32 . A method for treating a subject with a disease or disorder, the method comprising:
a. obtaining a biological sample from the subject;
b. assaying the biological sample for one or more Ras mutations;
c. determining if one or more Ras mutations are present in the biological sample; and
d. administering to the subject one or more tyrosine kinase inhibitors and one or more inhibitors of the DHFR pathway where one or more Ras mutations are present in the biological sample and administering to the subject one or more tyrosine kinase inhibitors where no Ras mutations are present in the biological sample.
33 . The method of claim 32 , wherein the inhibitor of the DHFR pathway is a methyltransferase inhibitor.
34 . The method of claim 33 , wherein the methyltransferase inhibitor is Methotrexate.
35 . The method of claim 32 , wherein the disease or disorder is characterized by one or more Ras mutations.
36 . The method of claim 35 , wherein Ras is k-Ras (SEQ ID NO: 1), n-Ras (SEQ ID NO: 2) or h-Ras (SEQ ID NO: 3).
37 . The method of claim 36 , wherein the k-Ras mutations are at position 12, 13 or 61.
38 . The method of claim 37 , wherein the k-Ras mutations are selected from the group consisting of: G12A, G12N, G12R, G12C, G12S, G12V, G13N and Q61H.
39 . The method of claim 36 , wherein the h-Ras or n-Ras mutations are at positions 12, 13 or 61.
40 . The method of claim 32 , wherein the receptor tyrosine kinase inhibitor is an antibody.
41 . The method of claim 40 , wherein the antibody is a monoclonal antibody.
42 . The method of claim 41 , wherein the monoclonal antibody is cetuximab (Erbitux), panitumumab zalutumumab, nimotuzumab or matuzumab.
43 . The method of claim 32 , wherein the receptor tyrosine kinase inhibitor is a small molecule inhibitor.
44 . The method of claim 43 , wherein the small molecule inhibitor is gefitinib, erlotinib or lapatinib.
45 . The method of claim 32 , wherein the therapeutically effective amount of one or more tyrosine kinase inhibitors and the therapeutically effective amount of one or more methyl-transferase inhibitors are optionally adapted for a co-treatment with radiotherapy or radio-immunotherapy.
46 . The method of claim 32 , wherein the disease or disorder is cancer.
47 . The method of claim 46 , wherein the cancer is selected from the group consisting of gastrointestinal cancer, prostate cancer, ovarian cancer, breast cancer, head and neck cancer, lung cancer, non-small cell lung cancer, cancer of the nervous system, kidney cancer, retina cancer, skin cancer, liver cancer, pancreatic cancer, genital-urinary cancer and bladder cancer.
48 . The method of claim 32 , wherein the subject is a cancer patient.
49 . The method of claim 32 , wherein the biological sample is assayed for Ras mutations by analyzing nucleic acid obtained from the sample.
50 . The method of claim 32 , wherein the biological sample is assayed for Ras mutations by analyzing proteins obtained from the sample.
51 . The method of claim 32 , wherein biological sample is a tumor biopsy.
52 . The method of claim 32 , wherein the biological sample is an aspirate.
53 . The method of claim 32 , wherein the tyrosine kinase inhibitor targets HER1 (EGFR), HER2/neu, HER3, or any combination thereof.
54 . A pharmaceutical composition comprising a therapeutically effective amount of one or more tyrosine kinase inhibitors and a therapeutically effective amount of one or more inhibitors of the DHFR pathway.
55 . The pharmaceutical composition of claim 54 , wherein the inhibitor of the DHFR pathway is a methyltransferase inhibitor.
56 . The pharmaceutical composition of claim 55 , wherein the methyltransferase inhibitor is Methotrexate.
57 . The pharmaceutical composition of claim 54 , wherein the receptor tyrosine kinase inhibitor is an antibody.
58 . The pharmaceutical composition of claim 57 , wherein the receptor tyrosine kinase inhibitor targets HER1 (EGFR), HER2/neu, HER3, or any combination thereof.
59 . The pharmaceutical composition of claim 57 , wherein the antibody is a monoclonal antibody.
60 . The pharmaceutical composition of claim 59 , wherein the monoclonal antibody is cetuximab (Erbitux), panitumumab zalutumumab, nimotuzumab or matuzumab.
61 . The pharmaceutical composition of claim 54 , wherein the receptor tyrosine kinase inhibitor is a small molecule inhibitor.
62 . The pharmaceutical composition of claim 61 , wherein the small molecule inhibitor is gefitinib, erlotinib or lapatinib.